Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA starts rolling review of Valneva's COVID-19 vaccine (VLA2001)

12/03/2021 | 08:24am EST

EMA's human medicines committee (CHMP) has started a rolling review of VLA2001, a COVID-19 vaccine being developed by Valneva.

The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults. These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.

EMA will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for a formal marketing authorisation application.

The Agency will assess the compliance of VLA2001 with the usual EU standards for effectiveness, safety and quality. While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review.

EMA will communicate further when the marketing authorisation application for the vaccine has been submitted.

How is the vaccine expected to work?

VLA2001 is expected to prepare the body to defend itself against infection with SARS-CoV-2, the virus that causes COVID-19. The vaccine contains inactivated (killed) SARS-CoV-2 that cannot cause the disease. VLA2001 also contains two 'adjuvants', substances to help strengthen the immune response to the vaccine.

When a person is given the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. If, later, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the virus and be ready to defend against it.

What is a rolling review?

A rolling review is a regulatory tool that EMA uses to speed up the assessment of a promising medicine or vaccine during a public health emergency. Normally, all data on a medicine or vaccine's effectiveness, safety and quality and all required documents must be ready at the start of the evaluation in a formal application for marketing authorisation. In the case of a rolling review, EMA's human medicines committee (CHMP) reviews data as they become available from ongoing studies. Once the CHMP decides that sufficient data are available, the company can submit a formal application. By reviewing the data as they become available, the CHMP can come to an opinion on the medicine's authorisation sooner.

During a rolling review, and throughout the pandemic, EMA and its scientific committees are supported by the COVID-19 EMA pandemic task force (COVID-ETF). This group brings together experts from across the European medicines regulatory network to advise on the development, authorisation and safety monitoring of medicines and vaccines for COVID-19 and facilitate quick and coordinated regulatory action.



Tel: +31 (0)88 781 8427

E-mail: press@ema.europa.eu

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about VALNEVA SE
01/25Valneva Includes Booster Shots in Late-Stage Study of COVID-19 Jab
01/25Valneva Starts Extended Trial to Study Booster Shot of COVID-19 Vaccine; Shares Up 9%
01/25Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine..
01/24EU Medicines Watchdog to Issue Decision on Pfizer's COVID-19 Pill in January
01/24EU regulator set to rule on Pfizer COVID pill by end-Jan, ahead of Merck
01/20Top Premarket Decliners
01/20EUROPEAN MIDDAY BRIEFING - Stocks Down After Mixed Asia Trading, US Fall
01/20Valneva Gains 20% as COVID-19 Jab Shows Effect Against Omicron in Preliminary Studies
01/20VALNEVA : Kepler Cheuvreux reiterates its Buy rating
01/19Valneva COVID-19 Jab Shows Effect Against Omicron After Three Doses in Phase 1/2 Study
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Sales 2021 103 M 117 M 117 M
Net income 2021 -146 M -165 M -165 M
Net cash 2021 148 M 168 M 168 M
P/E ratio 2021 -9,82x
Yield 2021 -
Capitalization 1 495 M 1 686 M 1 689 M
EV / Sales 2021 13,0x
EV / Sales 2022 2,36x
Nbr of Employees 700
Free-Float 76,5%
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | MarketScreener
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 14,21 €
Average target price 22,38 €
Spread / Average Target 57,5%
EPS Revisions
Managers and Directors
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Peter Buhler Chief Financial Officer & Director
FrÚdÚric Grimaud Chairman-Supervisory Board
Michael M÷hlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-42.00%1 686
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875